Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$34.78 USD
-2.77 (-7.38%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $34.75 -0.03 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLDX 34.78 -2.77(-7.38%)
Will CLDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Acadia Healthcare (ACHC) Beats Q2 Earnings and Revenue Estimates
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Other News for CLDX
Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Celldex (CLDX)
Celldex: Latest Urticaria Data Gives Market Jitters - I'm On Sidelines
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Celldex selloff on anaphylaxis concerns overdone, says TD Cowen